| Recruiting | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT06616155 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial NCT06632977 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Recruiting | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic C NCT06305598 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Com NCT06470243 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistan NCT06236139 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients NCT05924672 | University of California, San Francisco | Phase 2 |
| Recruiting | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPS NCT06288113 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castrat NCT05805371 | City of Hope Medical Center | Phase 1 |
| Recruiting | Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, NCT06039371 | University of Washington | Phase 2 |
| Recruiting | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT06200103 | Mayo Clinic | Phase 2 |
| Recruiting | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Pr NCT05398302 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant NCT05730712 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mu NCT05689021 | Mayo Clinic | Phase 2 |
| Withdrawn | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Tre NCT05807126 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer NCT05828082 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma NCT04951492 | University of Washington | Phase 2 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT05479578 | Rashmi Verma, MD | Phase 1 |
| Completed | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant NCT05547386 | Mayo Clinic | Phase 3 |
| Recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoC NCT05168618 | University of Utah | Phase 2 |
| Terminated | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05037500 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate C NCT04455750 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer NCT04716725 | Thomas Hope | Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant NCT04489719 | University of Washington | — |
| Withdrawn | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03709550 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT04471974 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of NCT04592237 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Terminated | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Re NCT04279561 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer NCT03503344 | University of California, San Francisco | Phase 2 |
| Terminated | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT04159896 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Unknown | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT04033432 | Northwestern University | Phase 2 |
| Active Not Recruiting | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer NCT03873805 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Pros NCT03517969 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer NCT03805594 | University of California, San Francisco | Phase 1 |
| Active Not Recruiting | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With NCT03317392 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small NCT03582475 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prosta NCT03344211 | University of Southern California | Phase 2 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer NCT03516812 | University of Washington | Phase 2 |
| Terminated | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556 | University of Washington | Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Withdrawn | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resis NCT03596710 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate C NCT03406858 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients W NCT03419234 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer NCT03456804 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant NCT03360721 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer NCT03448458 | Emory University | Phase 2 |
| Active Not Recruiting | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With NCT02893917 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in NCT02703623 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cance NCT02565901 | University of Washington | Phase 1 / Phase 2 |
| Completed | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin NCT02598895 | University of Washington | Phase 2 |
| Completed | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer NCT02532114 | University of Washington | Phase 1 |
| Completed | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prost NCT02555189 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Active Not Recruiting | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer NCT02522715 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated Wit NCT02312557 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide NCT02099864 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer NCT01881867 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant NCT02228265 | OHSU Knight Cancer Institute | — |
| Completed | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Res NCT01505868 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-R NCT01576172 | National Cancer Institute (NCI) | Phase 2 |